Key Laboratory of Longevity and Aging-Related Disease of the Chinese Ministry of Education, Guangxi Medical University, Nanning, Guangxi, China (mainland).
Center for Translational Medicine and School of Basic Medical Sciences, Guangxi Medical University, Nanning, Guangxi, China (mainland).
Med Sci Monit. 2021 Apr 19;27:e929199. doi: 10.12659/MSM.929199.
BACKGROUND The goal of this study is to verify that the loss of speckle-type POZ protein (SPOP) promotes the migration and invasion of prostate cancer cells, and that this process is brought about by an increase in MCP-1. MATERIAL AND METHODS SPOP knockout C4-2 cells (C4-2 SPOP-/-) were verified by western blotting. Transwell and wound-healing assays were applied to verify different migration and invasion abilities between the C4-2 SPOP-/- and control cells. We used an antibody array to find different soluble chemokine factors in the C4-2 SPOP-/- cells. ELISA and qRT-PCR were applied for confirmation. To test MCP-1 function in conditioned medium, a transwell assay was applied with or without anti-MCP-1 antibody. RESULTS The western blot showed that SPOP was knocked out in sgSPOP-1 and sgSPOP-2 (different clones of C4-2 SPOP-/-). The transwell and wound-healing assays indicated that, compared with control cells, sgSPOP-1 and sgSPOP-2 had stronger migration and invasion abilities. The antibody array found that the expression of MCP-1 was upregulated in sgSPOP-1 and sgSPOP-2 conditioned medium. This result was verified by ELISA and qRT-PCR. In the prostate cancer cells, migration and invasion activity was greatly increased in C4-2 SPOP-/- conditioned medium, while this activity was decreased after anti-MCP-1 antibody neutralization. CONCLUSIONS Our findings suggest that the loss of SPOP in C4-2 cells promotes increased cell migration and invasion abilities. This may be realized by upregulating the expression of MCP-1. The inhibition of MCP-1 expression may be an effective treatment for SPOP-mutant prostate cancer.
本研究旨在验证斑点型 POZ 蛋白(SPOP)缺失可促进前列腺癌细胞的迁移和侵袭,且该过程是通过 MCP-1 的增加来实现的。
通过 Western blot 验证 SPOP 敲除 C4-2 细胞(C4-2 SPOP-/-)。应用 Transwell 和划痕实验验证 C4-2 SPOP-/-和对照细胞之间不同的迁移和侵袭能力。我们使用抗体阵列在 C4-2 SPOP-/-细胞中寻找不同的可溶性趋化因子因子。应用 ELISA 和 qRT-PCR 进行验证。为了测试条件培养基中 MCP-1 的功能,应用 Transwell 实验,同时或不使用抗-MCP-1 抗体。
Western blot 显示 sgSPOP-1 和 sgSPOP-2(C4-2 SPOP-/-的不同克隆)中敲除了 SPOP。Transwell 和划痕实验表明,与对照细胞相比,sgSPOP-1 和 sgSPOP-2 具有更强的迁移和侵袭能力。抗体阵列发现 sgSPOP-1 和 sgSPOP-2 条件培养基中 MCP-1 的表达上调。该结果通过 ELISA 和 qRT-PCR 得到验证。在前列腺癌细胞中,C4-2 SPOP-/-条件培养基中细胞迁移和侵袭活性大大增加,而在用抗-MCP-1 抗体中和后,该活性降低。
我们的研究结果表明,C4-2 细胞中 SPOP 的缺失促进了细胞迁移和侵袭能力的增强。这可能是通过上调 MCP-1 的表达来实现的。抑制 MCP-1 的表达可能是治疗 SPOP 突变型前列腺癌的有效方法。